FINNENCE ▪ THE WIRE FILE
THE WIRE · № 65450
News■ Unclear/unknown
Vial Doses First Patient with Asthma in Phase 1b Study of Vial's IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 15:42 UTC
LAST UPDATE2026-10-05 15:42 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Early-stage bispecific antibody dosing; no ticker or financial terms given.
Clinical milestone, but no listed issuer named
CATALYST TO WATCH
Future Phase 1b data readout
MAIN RISK
Early-stage failure before approval
FULL DISPATCH
Vial's IL-13 x TSLP is designed to deliver breadth, depth, and durability of Type 2 disease control in a single half-life-extended antibody Phase 1a data in healthy volunteers (15–800 mg IV) support progression into patients, with pharmacokinetics that could support twice-yearly (Q6M)...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Nolla Health Announces Nation's First AI to Issue Initial Prescriptions2026-10-05 16:00 UTC
Nolla Health Announces Nation's First AI to Issue Initial Prescriptions2026-10-05 16:00 UTC
→CORRELATIONshares Healthcare
Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.2026-10-05 16:41 UTC
Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.2026-10-05 16:41 UTC
→CORRELATIONshares Healthcare
AHN Cardiology Department at Allegheny General Hospital Launches Clinical Trial Investigating New Therapy for Pulmonary Arterial Hypertension2026-10-05 17:45 UTC
AHN Cardiology Department at Allegheny General Hospital Launches Clinical Trial Investigating New Therapy for Pulmonary Arterial Hypertension2026-10-05 17:45 UTC
→CORRELATIONshares Healthcare
IVD Quality Control Market to Reach US$ 2.2 Bn by 2031, Growing at 5.3% CAGR as Labs Shift to Automated QC Workflows: New Report by Wissen Research2026-10-05 18:01 UTC
IVD Quality Control Market to Reach US$ 2.2 Bn by 2031, Growing at 5.3% CAGR as Labs Shift to Automated QC Workflows: New Report by Wissen Research2026-10-05 18:01 UTC
→CORRELATIONshares Healthcare
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma2026-10-05 18:54 UTC
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma2026-10-05 18:54 UTC
→CORRELATIONshares Healthcare
CPI | Invisalign Maker Must Face Renewed Antitrust Litigation2026-10-05 18:41 UTC
CPI | Invisalign Maker Must Face Renewed Antitrust Litigation2026-10-05 18:41 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.